Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Down 2.6%

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report)'s share price was down 2.6% during mid-day trading on Thursday . The stock traded as low as $909.80 and last traded at $911.41. Approximately 52,408 shares were traded during mid-day trading, a decline of 89% from the average daily volume of 481,136 shares. The stock had previously closed at $936.20.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on REGN shares. Cantor Fitzgerald raised their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $925.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 6th. Truist Financial reiterated a "buy" rating and set a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Barclays lifted their price target on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an "overweight" rating in a research note on Tuesday, January 23rd. BMO Capital Markets lifted their price target on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an "outperform" rating in a research note on Monday, February 5th. Finally, Morgan Stanley lifted their price target on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 13th. Four analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $968.67.

Regeneron Pharmaceuticals Price Performance

The stock has a fifty day moving average of $958.37 and a 200-day moving average of $888.22. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $101.01 billion, a P/E ratio of 26.48, a PEG ratio of 2.74 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The business had revenue of $3.43 billion during the quarter, compared to analysts' expectations of $3.29 billion. During the same period in the previous year, the business posted $10.96 earnings per share. The firm's revenue for the quarter was up .6% compared to the same quarter last year. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.18 EPS for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In related news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares in the company, valued at $46,203,239.82. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, EVP Marion Mccourt sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the completion of the sale, the executive vice president now directly owns 13,789 shares in the company, valued at $12,888,716.19. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares of the company's stock, valued at $46,203,239.82. The disclosure for this sale can be found here. Insiders sold 13,729 shares of company stock valued at $13,124,641 over the last ninety days. 8.83% of the stock is owned by insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several institutional investors have recently modified their holdings of REGN. Markel Corp grew its position in shares of Regeneron Pharmaceuticals by 1.3% during the 1st quarter. Markel Corp now owns 80,300 shares of the biopharmaceutical company's stock worth $56,083,000 after buying an additional 1,000 shares during the period. Cibc World Market Inc. grew its position in shares of Regeneron Pharmaceuticals by 1.4% during the 1st quarter. Cibc World Market Inc. now owns 6,416 shares of the biopharmaceutical company's stock worth $4,481,000 after buying an additional 86 shares during the period. Blair William & Co. IL grew its position in shares of Regeneron Pharmaceuticals by 18.4% during the 1st quarter. Blair William & Co. IL now owns 1,431 shares of the biopharmaceutical company's stock worth $999,000 after buying an additional 222 shares during the period. Sequoia Financial Advisors LLC grew its position in shares of Regeneron Pharmaceuticals by 23.1% in the 1st quarter. Sequoia Financial Advisors LLC now owns 495 shares of the biopharmaceutical company's stock valued at $346,000 after purchasing an additional 93 shares during the period. Finally, Baird Financial Group Inc. grew its position in shares of Regeneron Pharmaceuticals by 100.9% in the 1st quarter. Baird Financial Group Inc. now owns 36,529 shares of the biopharmaceutical company's stock valued at $25,513,000 after purchasing an additional 18,345 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.